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The present narrative review is the first in a series of reviews about the appropriate conduct 
in substance-assisted psychotherapy (SAPT). It outlines a current perspective onpreconditions 
and theoretical knowledge that have been identified as valuable in the literaturefor appropriate 
therapeutic conduct in SAPT. In this context, considerations regarding ethics and the spiritual 
emphasis of the therapeutic approaches are discussed. Further, current methods, models, 
and concepts of psychological mechanism of action and therapeutic effects of SAPT are 
summarized, and similarities between models, approaches, and potential mediators for 
therapeutic effects are outlined. It is argued that a critical assessment of the literature might 
indicate that the therapeutic effect of SAPT may be mediated by intra- and interpersonal 
variables within the therapeutic context rather than specific therapeutic models per se. The 
review provides a basis for the development and adaptation of future investigations, therapeutic 
models, training programs for therapists, and those interested in the therapeutic potential of 
SAPT. Limitations and future directions for research are discussed.
Keywords: substance-assisted psychotherapy, psychotherapy, psychedelics, therapeutic rationale, therapeutic 
conduct
INTRODUCTION
Research on psychotherapy utilizing psychoactive substances, subsequentially referred to as 
substance-assisted psychotherapy (SAPT), has been re-established in the 21st century. This 
renewed interest has been referred to as the “psychedelic renaissance” (Sessa, 2012). It has 
followed a period in which these substances were stigmatized, not due to their international 
prohibition in 1971 since the early evidence collected on SAPT suggested psychedelics could 
be effective in treating a variety of mental health conditions; but rather, due to the circumstances 
in which they were prohibited (Grinspoon and Bakalar, 1979). With public and professional 
interest in SAPT rapidly growing, this narrative review presents the perspective on the necessary 
preset (i.e., valuable preconditions and knowledge) for practicing SAPT that has been identified 
in the current literature on the topic.
The recent growth in research has included clinical trials demonstrating the safety and 
efficacy of this approach for treatment refractory post-traumatic stress disorder (PTSD; 
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Mithoefer et al., 2019), alcohol dependence (Bogenschutz et al., 
2015), as well as anxiety and depression associated with end 
stage cancer (Agin-Liebes et  al., 2020). Open label trials 
have  also  indicated that psychedelic-assisted psychotherapy 
could be  effective in treating obsessive–compulsive disorder 
(Moreno  et  al., 2006), treatment-resistant depression (TRD; 
Carhart-Harris et al., 2016), and nicotine dependence (Johnson 
et  al., 2017). Although there is recent progress in recording 
the safety and effectiveness of these approaches paving the 
way for their potential implementation and application in 
clinical practice (e.g., Kargbo, 2020; Nichols, 2020), the 
mechanisms responsible for therapeutic change across different 
psychotherapeutic approaches are still not fully understood.
Classic psychedelics (e.g., LSD, psilocybin, DMT and 
mescaline) are regarded as non-addictive and do not appear 
to present an independent risk factor for mental health problems 
(Krebs and Johansen, 2013; Johansen and Krebs, 2015; Hendricks 
et  al., 2015). Meanwhile, other psychoactive substances with 
subjective effects that are similar to psychedelics, such as 
ketamine (Krupitsky and Grinenko, 1997; Serafini et al., 2014), 
MDMA (Thal and Lommen, 2018) and ibogaine (Alper, 2001), 
are being investigated as for their potential use in SAPT.
Classic psychedelics and MDMA have been found to produce 
acute and persistent positive personality changes (Bouso et al., 
2018) and improved well-being in healthy individuals (Elsey, 
2017; Jungaberle et  al., 2018). These substances have been 
linked to heightened mindfulness (Soler et  al., 2016, 2018), 
a sense of connection to nature (Forstmann and Sagioglou, 
2017), creativity (Kuypers et  al., 2016; Uthaug et  al., 2018; 
Mason et al., 2019), and openness (Liechti et al., 2017). Many 
researchers have called for more extensive research into the 
potential of the clinical applications of these substances, 
particularly in respect to the current mental health crisis 
(see Belouin and Henningfield, 2018; Schenberg, 2018) and 
the limited awareness of their potential amongst health care 
professionals (Barnett et  al., 2018).
It is becoming increasingly apparent that the potential 
effects of SAPTs are dependent on several contextual factors, 
including psychological preparation prior to the experience 
(Johnson et  al., 2008), extra-pharmacological manipulations 
in the form of specific music playlists (Kaelen et  al., 2018), 
and psychological integration subsequent to the experience 
(Hartogsohn, 2017; Richards, 2017; Carhart-Harris et al., 2018; 
Garcia-Romeu and Richards, 2018). Key components that 
meditate the therapeutic alliance (e.g., unconditional acceptance 
and therapeutic presence) and have been shown to be  strong 
predictors of outcome in traditional psychotherapy (Frank 
and Frank, 1991; Geller and Greenberg, 2012; Norcross and 
Lambert, 2018), are also likely play a vital role in SAPT 
(Greer and Tolbert, 1998; Garcia-Romeu and Richards, 2018).
In this narrative review, we  will summarize valuable 
considerations, methods, models, and current (theoretical) 
concepts regarding the psychological mechanism of action and 
therapeutic effects of SAPT that are identified in the literature. 
Thereby, we highlight similarities between models and approaches 
to outline potential mediators for therapeutic effects. Further, 
we  critically discuss literature indicating that various schools 
of psychotherapy may translate and incorporate their approaches 
to SAPT. This article is intended to provide the preface (or 
preset) to a series of systematic and narrative reviews examining 
each stage of the SAPT treatment process, by outling the 
valuable prerequise knowledge for psychotherapists interested 
in practicing SAPT. In doing so, we  have not considered the 
additional medical training and knowledge required to provide 
SAPT (e.g., physiological conditions and concomitant 
mediucations that would contraindicate SAPT) in this article 
since it is not within our scope of clinical practice.
ETHICAL CONSIDERATIONS
There are strict conditions and frameworks required by ethical 
committees of universities and research institutes currently 
investigating SAPT, extensive bureaucratic and jurisdictional 
exchange with government institutions, and cautious storage, 
documentation, and safety procedures are necessary to conduct 
research in this field (Strassman, 2001; Johnson et  al., 2008; 
Bogenschutz, 2013; Nutt et  al., 2013). While standard ethical 
guidelines apply to SAPT, additional considerations are vital. 
The Council on Spiritual Practices offers a code of ethics for 
spiritual guides that provides a framework for guiding people 
through exceptional states of consciousness that can be transferred 
to therapeutic sessions with psychoactive substances (Jesse, 2001). 
Therein, it is firmly highlighted that it is crucial for therapists 
to be  well-intended and empathetic towards their clients due 
to augmented transference, counter-transference, and suggestibility 
(Leary, 1961; Fadiman, 2011; Carhart-Harris et  al., 2015). As 
such, risks (both physical and psychological) should be discussed, 
preventive measures should be  taken, and the client should 
be educated on the comparatively rapid transformative potential 
of the therapy (see Griffiths et  al., 2006).
Therapists should be  aware of the possibility of substance-
occasioned uncomfortable material (sexual, or traumatic), and 
be  prepared to respond to this using methods and techniques 
for which they are qualified through education, training, and 
experience (Grof, 2000; Phelps, 2017). In these situations, 
therapists need to simultaneously help clients process this 
material and prevent colluding with clients in acting out 
inappropriately (see Grof, 2000). Therapists and clients should 
agree upon limits on behaviors prior to the session. Such 
limitations could include outlining the parameters for appropriate 
touch, prohibiting self-harm, violence against facilitators and 
others, destruction of property, and sexual acting out 
(Mithoefer, 2017).
Increased vulnerability to suggestions and manipulations 
due to the heightened suggestibility in psychedelic states was 
identified in healthy volunteers after the administration of LSD 
(Carhart-Harris et  al., 2015). This vulnerability, combined with 
increased attribution of certain ideas holding personal meaing 
or perceiving the ideas and contents experienced under the 
influence of psychedelics to hold greater noetic truth value in 
both healthy and clinical samples (Timmermann et  al., 2020), 
may lead to reduced agency and judgment when compared 
to regular psychotherapy sessions. Even simple misunderstandings 
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might be more likely to occur and the validation and mediation 
of the content and knowledge experienced in these states raises 
important ethical considerations: the increased risk of iatrogenic 
complications (e.g., false memory syndrome; Pope, 1996) through 
induced noetic feelings of revelation. Timmermann et al. (2020) 
propose a pragmatic framework founded on an ethical approach 
embedding these experiences within larger cultural- and historical 
contexts while considering their intersubjective character. They 
stress the importance of validation based on empathy by an 
experienced therapist to facilitate appropriate processing and 
integration of these experiences while considering aforementioned 
challenges. There is also an increased importance for therapists 
to be  aware of the limitations on scope of practice required 
by most psychotherapy regulatory bodies, including preventing 
clients from being exploited, and therapists having an awareness 
of their own limitations, values, needs, and beliefs. Most 
importantly, therapists should be  open for regular peer-review 
and seek council and feedback from other practitioners as 
required by most professional bodies. This is of utmost importance 
in SAPT because of the strict legal framework that must 
be  considered and the aforementioned elevated potential for 
misperception and misjudgment.
The need for therapists’ self-experience with altered states of 
consciousness and substances that are administered in SAPT is 
controversial. For example, Forstmann and Sagioglou (2021) found 
that the perception of a reserachers’ integrity and quality of their 
research by psychedelic naïve participants was reduced if the 
researcher self-admitted substance use (Forstmann and Sagioglou, 
2021). While there will likely be  a continuum amongst therapists 
engaged in SAPT clinical trails, ranging from those without any 
personal experiences to those with a vast amount of experience 
across substances and settings, open discussion of these experiences 
can be constrained for fear of personal, professional, and sometimes 
legal consequences (Nielson and Guss, 2018; Ross et  al., 2020). 
Some practitioners in the field regard personal experiences with 
these substances as essential in order to emphasize with the client’s 
experiences (Metzner, 1998; Bogenschutz, 2013; Bogenschutz and 
Forcehimes, 2017) and in certain countries, such as Switzerland, 
personal experience is required for therapists to work with clients 
in SAPT settings (Grof, 2000; Strassman, 2001). However, personal 
experiences may lead some therapists to become less curious 
about the client if they believe that their clients’ experience will 
be  similar to their own (Bogenschutz, 2013; Bogenschutz and 
Forcehimes, 2017). Thus, personal experience is a double edged 
sword that may be  a potential confound to research and SAPT, 
though has not yet been empirically investigated (Nielson and 
Guss, 2018). Also, in line with standard ethical guidelines, we believe 
that therapists should not take any mind-altering substances before 
or during therapy sessions, regardless of whether they are providing 
SAPT or regular psychotherapy.
SPIRITUAL EMPHASIS OF THE 
THERAPY
Substance-occasioned spiritual or mystical experiences have 
been described as ineffable, noetic, and sacred, involving time 
dilation and ego dissolution (Griffiths et al., 2006, 2008; MacLean 
et al., 2011). They may be compared to non-substance-induced 
personal encounters with God, a divine entity, or Ultimate 
Reality (Griffiths et al., 2019). Such research using psychometric 
outcome measures was first conducted at Harvard overy 50 
years using a 43-item tool develop by Pahnke (1969). More 
recent research has typically used a 30 item iteration of this 
tool (the revised Mystical Experience Qusetion; MacLean et al., 
2012), which appears to have more robust psychometric properties 
(Barrett et  al., 2015).
Since this therapeutic experience may be  regarded as one 
of the most meaningful experiences of the clients’ lives (Griffiths 
et  al., 2006, 2008; MacLean et  al., 2011; Preller et  al., 2017; 
Schmid and Liechti, 2018), Garcia-Romeu and Richards (2018) 
have proposed that therapists consider treating it accordingly 
throughout the entire therapeutic process. Adamson and Metzner 
(1988) have claimed that even though therapists may not 
be  religious themselves and exclude these aspects from their 
usual work, spiritual perspectives on the experience that may 
arise in the clients engaged in SAPT should be  respected and 
supported. While an emphasis on specific religious systems 
has been discouraged by Grof (2000), he  has proclaimed it 
as useful to focus on the awareness of the aesthetic aspects 
of the world, basic philosophical questions of life, and the 
recognition of spiritual dimensions of existence in a non-specific 
way. Meanwhile, Stolaroff (2004) has propsoed that unless 
clients are using the word “spiritual,” it might be  advisable to 
avoid labels, due to the danger of enhanced suggestibility. 
Importantly, avoiding the psychological blockages and focusing 
on the repetition of spiritual experiences (i.e., spiritual bypassing), 
may constitute a pitfall for therapeutic progress, with Frecska 
et  al. (2016) cauitioning that it may result in avoidance of 
the real psychological issues and an unhealthy relationship 
with spiritual aspects of substance-induced experiences.
As outlined below, therapeutic approaches that integrate 
contemplative spiritual practices like third wave behavior therapies 
(TWBTs) have been identified as valuable frameworks for SAPT 
in the literature (Walsh and Thiessen, 2018). Recent research 
investigating the interaction between meditation and psilocybin 
found potential synergistic effects of meditation practices and 
mystical experiences or ego dissolution occasioned by psilocybin 
(Griffiths et  al., 2018; Smigielski et  al., 2019). This finding 
may suggest that the development of mindfulness- or other 
spiritual or meditative practices through the preparatory and 
integration stages of therapy could potentiate the treatment 
effects (Walsh and Thiessen, 2018).
MECHANISM OF ACTION AND 
THERAPEUTIC EFFECTS OF 
SUBSTANCE-ASSISTED 
PSYCHOTHERAPY
It is predominantly believed that the therapeutic effects of substance-
assisted treatments are a combination of the psychopharmacological 
effects of the substance (e.g., see Carhart-Harris et  al., 2014; 
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Carhart-Harris and Friston, 2019; Preller et  al., 2019), which 
influence the client’s intrapsychic experience, but also the shared 
interpersonal experience between client and therapist (Adamson 
and Metzner, 1988), the mindset of the client and the therapist, 
and successful psychotherapeutic integration of the experience 
(Mithoefer, 2017; Bogenschutz et  al., 2018; Malone et  al., 2018). 
Thereby, the quality, intensity, and duration of challenging parts 
of the acute psychedelic experience may be  key mediators for 
the therapeutic outcome (Carbonaro et  al., 2016; Roseman et  al., 
2018). However, the acute and long-term or persistent effects 
(more relevant for treatment effects) differ substantially 
(Carhart-Harris et  al., 2016), so the specific psychological 
mechanisms that account for their therapeutic efficacy are still 
not comprehensively understood. Various acute and persistent 
effects of psychedelics and entactogens were outlined by Jungaberle 
et al. (2018) and include, amongst others, positive effects on well-
being, mood, empathy, cognitive flexibility, self-transcendence, and 
openness. However, individual experiences might be  extremely 
variable and generalizations based on single sessions and small 
sample sizes are problematic (Grof, 2000; Bogenschutz et al., 2018) 
due to different personality structures of the client (Sandison and 
Whitelaw, 1957; Cohen, 1960; Gucker, 1963) amongst other 
individual differences. Consequently, attempts to depict and 
generalize the psychological mechanisms of action rendering SAPT 
an effective treatment option for certain disorders draw on similar 
terminologies to frame distinct theoretical concepts. These concepts 
may not be mutually exclusive (i.e., they tend to partially intersect). 
Thus, significant differences seem to be  more evident in the 
theoretical foundations the concepts stem from rather than their 
conclusions. In this section, we  have attempted to merge these 
concepts as derived from diverse models into meaningful clusters. 
We  have also not attempted to distinguish the moderating factor 
of which psychedelics could differentially contribute to each 
mechanism, as the literature at present does not seem advanced 
enough for such an analysis.
Personal Significance, Insights, and 
Meaningfulness
Early psychedelic research assumed that a heightened sense 
of significance and meaningfulness (also described as 
prolonged “eureka” experience) under the influence of certain 
substances contributed to the therapeutic effects (Ludwig and 
Levine, 1965b). Material encountered during substance-assisted 
sessions is usually personal and uniquely meaningful (Griffiths 
et  al., 2006, 2008; MacLean et  al., 2011; Preller et  al., 2017; 
Schmid and Liechti, 2018) and relevant to the facilitation 
of personal growth in each client (Cutner, 1959; Shanon, 2003;  
Bogenschutz et  al., 2018).
The importance of personal meaning has been highlighted 
in various empirical studies. In a randomized, double-blind, 
active placebo-controlled study, 29 participants experiencing 
cancer-related anxiety and depression received a single-dose 
of psilocybin in conjunction with psychotherapy (Ross et  al., 
2016). Through synthesizing prior qualitative analyses of 
interviews with these participants (Belser et  al., 2017; Swift 
et al., 2017), with a qualitative analysis of their written narratives 
and their therapists’ notes, Malone et  al. (2018) found that 
psilocybin may support clients in gaining insight regarding 
the root cause of their issues or disorders due to the personalized 
nature of the subjective experiences that seems to be  tailored 
to individual psychological needs.
This hypothesis is supported from the results of a pilot 
study of 13 participants (N = 9 with diagnoses of substance 
abuse and/or dependence) in which self-report measures of 
the Purpose of Life Test significantly increased at three and 
nine-month follow ups after treatment with Ayahuasca (Fernández 
et  al., 2013). In another study, 36 participants without prior 
experience with psychedelics received psilocybin or placebo 
in a double-blind counterbalanced design (Griffiths et al., 2006). 
In a 14-month follow-up, 58% of the participants assessed the 
experience as one of the five most personally meaningful 
experiences of their lives with 64% indicating persistent increases 
in life-satisfaction or well-being (Griffiths et al., 2008). Similarly, 
13 of 15 (i.e., 86%) participants in a one-year follow-up of a 
psilocybin-facilitated smoking cessation trial rated the experience 
amongst the five most meaningful experiences of their lives 
(Johnson et al., 2017) and 10 of 14 (i.e., 71%) healthy volunteers 
in an LSD study rated the experience as one of the ten most 
meaningful experiences of their lives at one-year follow-up 
(Schmid and Liechti, 2018). Personally meaningful and emotional 
experiences with mystical qualities or ego dissolution are now 
thought to have causal links to persisting positive effects 
(Bogenschutz and Ross, 2016).
Awe and Peak-Experiences
Awe can be  defined as an emotion that is associated with 
profound pleasure bordering on fear while appreciating vastness 
(perceiving various stimuli as larger than the self) and 
accommodation (the need to revise mental structures to integrate 
novel experiences and perspectives; Keltner and Haidt, 2003). 
It is hypothesized that the profound awe that characterizes 
peak experiences occasioned by psychedelics may require 
habituated mental structures to accommodate to integrate and 
account for these novel perceptions and experiences. This 
process of cognitive re-accommodation may result in 
disorientation, fear, ego dissolution, and subsequent feelings 
of ultimate knowledge and enlightenment – once new information 
can be assimilated through the adaptation of mental structures 
(Hendricks, 2018). As a result, the profound feeling of awe 
may encourage one to superordinate the social collective to 
one’s individual needs, i.e., decrease egocentrism (Bai et  al., 
2017), and thus facilitate cooperation (Gowdy and Krall, 2015), 
shift attention to the presence while expanding experience of 
time (Rudd et al., 2012), and decrease tolerance for uncertainty 
which in turn elevates the inclination to acknowledge the 
influence of supernatural agents in experiences (Valdesolo and 
Graham, 2014). Thus, the sense of heightened connectedness 
or oneness with others and the universe (Carhart-Harris et  al., 
2018), and the shift of attention towards the collective and 
away from the self are theorized to constitute the positive 
treatment effects of psychedelics across a range of disorders 
(see Hendricks, 2018).
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Reconditioning
One potential mechanism of change in SAPT is the breaking 
of previously rigid maladaptive emotional and cognitive patterns, 
prior to them being reformed and reintegrated in a new 
structure (Frecska, 2011). This has been referred to as 
“restructuring,” “retraining” or “reconditioning” treatment 
(Spencer, 1964). The process can be  seen as a “secure form 
of regression” (Frecska, 2011), in which old associations are 
broken down and unlearned. Thus, previously frightening stimuli 
could lose their association with threat, and become deconditioned, 
before being reintegrated in a less problematic way. This has 
also been described as “de-patterning” (Gasser et  al., 2015). 
Neuroscientific evidence suggests that hyperexcitation in layer 
V pyramidal neurons mediated by the 5-HT2A agonism of 
psychedelics may disrupt fixated and conditioned cognitions, 
psychological habits, and constraints on internal generative 
models (Swanson, 2018). Disinhibition of these neurons may 
reduce the rigidity of higher-level beliefs (in a hierarchical 
predictive processing model) making them more receptive for 
bottom-up prediction errors (Carhart-Harris and Friston, 2019). 
Thereby, prior fixed beliefs may be  more easily challenged and 
restructured by novel information. This might be  reflected by 
lasting changes in attitudes (i.e., increased openness and 
extraversion and decreased neuroticism; Erritzoe et  al., 2018) 
and beliefs in individuals who used psychedelics (Nour et  al., 
2017; Jungaberle et  al., 2018).
Perspective-Shifts and Cognitive Flexibility
Another proposed mechanism of action is perspective-shifts or 
cognitive flexibility. Seemingly, this mechanism can be interpreted 
as a combination of a restructuring or shifting of pre-existing 
concepts through experiences that carry emotional and/or 
intellectual value (see Section "Awe and Peak-Experiences"). New 
perspectives and insights might be  gained and more rapidly 
accepted because of a novel sense of emotional and intellectual 
appreciation occasioned by the substance (Ludwig and Levine, 
1965a). Some authors suggest that processing of significant 
emotional or intellectual content, combined with loosened ego 
functions in an altered emotional state, may allow for a reduction 
of ruminations and egocentricity (Northoff, 2007; Pizzagalli, 
2011) wherein novel perspectives may be  gained (Leuner, 1967; 
Carhart-Harris et  al., 2014) and problems may be  appreciated 
for their true significance (Hofmann and Ott, 1980). The potential 
for a client to experience an alternative view of themselves has 
been referred to as “stripping away layers of onions” by some 
therapists (Cattell, 1957, p.  227). Gasser et  al.'s (2015) mixed 
methods data from 10 participants who received LSD-assisted 
psychotherapy suggest that amongst other variables, the cognitive 
experience (i.e., altered cognitive associations allowing for novel 
perspectives on intra- and interpersonal problems and 
relationships) mediates positive outcomes.
In a phenomenological discussion of the Ayahuasca 
experience, Shanon (2003), reported shifts in the locus of 
consciousness, self-consciousness, and personal identity (i.e., 
positive self; see Griffiths et  al., 2008) that may result in 
heightened cognitive flexibility and support the adaptation 
to different contexts (Franquesa et al., 2018). Subjective feelings 
of increased connection with oneself were linked to positive 
treatment effects of Ayahuasca for substance use in an 
observational study of 12 participants in a retreat combining 
4 days of group counseling and two Ayahuasca sessions 
(Thomas et  al., 2013).
Ayahuasca and psilocybin were both shown to have acute 
and prolonged effects on cognitive-thinking style (Kuypers 
et  al., 2016; Uthaug et  al., 2018; Mason et  al., 2019) and 
positive treatment effects of psilocybin may results from shifts 
in self-representation (Smigielski et al., 2019). Neurocognitively, 
these shifts may be  linked to enhanced cognitive flexibility 
(Gallimore, 2015) and altered neural connectivity (Tagliazucchi 
et  al., 2016; Carhart-Harris et  al., 2017; Preller et  al., 2019). 
This may also be  reflected in changes in personality measures 
like decreased neuroticism and increased conscientiousness and 
extraversion (i.e., openness) that have been observed in an 
open-label trial of 20 participants with moderate to severe 
TRD (Erritzoe et  al., 2018).
Qualitative data (Watts et  al., 2017) from aforementioned 
open-label study investigating psilocybin for TRD (Carhart-
Harris et  al., 2016) suggests that psychedelics combined with 
psychotherapy may increase psychological flexibility more than 
psychotherapy itself (Watts and Luoma, 2020). It is suggested 
that increased psychological flexibility may mediate therapeutic 
effects (Hayes et  al., 2012) in Acceptance and Commitment 
Therapy (ACT). This has led some authors (e.g., Sloshower 
et  al., 2020; Wolff et  al., 2020) to suggest that ACT might 
exhibit synergistic therapeutic mechanisms with SAPT. However, 
these speculations have yet to be  verified.
Mindfulness and Acceptance
Mindfulness and acceptance are important aspects of TWBT 
that share conceptual links and presumptions with the mechanisms 
outlined above. Namely, Wolff et  al. (2020) proposed that shifts 
from experiential avoidance to acceptance (which is closely 
related to mindfulness-practices and a mediator of therapeutic 
effects in TWBTs) may be  facilitated by the relaxation or 
disinhibition of higher level avoidance-related beliefs (see Sections 
“Reconditioning” and “Perspective-Shifts and Cognitive 
Flexibility”), elicitation and intensification of private events (see 
Section “Personal Significance, Insights, and Meaningfulness”), 
and operant conditioning of acceptance. During substance-assisted 
experiences, avoiding aversive aspects of the experience may 
increase adverse responses, while acceptance of the experiences 
may result in more rewarding responses (this was termed 
“avoidance sensitivity”). This results in the operant conditioning 
of acceptance instead of avoidance. The conditioned openness 
and acceptance may allow for exposure and consideration of 
private events that would otherwise be  avoided. As a result, 
previously held beliefs may be  revised during the relaxation 
of avoidance-related beliefs since this state allows for strong 
experiential contradictions to negative expectancies, i.e., the 
experience of oceanic boundlessness, blissful ego dissolution, 
and long-term increases in well-being (Wolff et  al., 2020).
Substance-induced dissociation from one’s learned roles and 
habits coupled with a conflict-free state of being may foster 
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acceptance of oneself. This hypothesis is supported by an 
independent group (N = 20 participants) self-report study 
comparing four consecutive Ayahuasca sessions with an eight-
week mindfulness-stress reduction (MBSR) course (Soler et al., 
2018). Results indicated that Ayahuasca and MBSR led to 
comparable increases in acceptance on the Non-Judging Subscale 
of the Five Facet Mindfulness Questionnaire. Meanwhile, a 
thematic analysis of semi-structured interviews of 20 participants’ 
accounts of an open-label trial of psilocybin for TRD at 6 
months follow-up found change processes from disconnection 
(from the self, fellow human beings, and the world) to connection 
and from emotional avoidance to acceptance (Watts et al., 2017).
The potential for more open exploration of psychodynamic 
connections has been noted in early psychedelic research 
(Hausner and Dolezal, 1963). Further, decentering – observing 
one’s feelings and thoughts in a detached manner (Kerr et  al., 
2011) – was positively associated with Ayahuasca use in a 
self-report study of 41 participants without prior experience 
with the substance and 81 experienced participants (Franquesa 
et al., 2018). In a randomized, double-blind, placebo-controlled 
study of 38 participants in a mindfulness retreat, a single 
psilocybin experience was linked to alterations in mood, social 
behavior, spirituality, and attitudes about life (Smigielski et  al., 
2019). Long-term increases in mindfulness following a single 
dose of psilocybin in ten psilocybin-naïve participants persisted 
for at least 3 months, even without explicit mindfulness training. 
This increase in mindfulness may represent a key mechanism 
of psilocybin therapy (Madsen et  al., 2020). Perceptual 
and  qualitative changes regarding intra- and interpersonal 
consciousness and perceived mindfulness capacities have also 
been reported by clients who have received SAPT. Bogenschutz 
et al. (2018) have proposed that these changes mediate positive 
treatment effects.
Re-assessment of Memories
Re-experiencing and re-assessing memories under the influence 
of certain substances may be  another mechanism of action 
underlying SAPT that evidences conceptual links to personal 
meaning and perspective-shifts. This overlap of mechanisms 
may be  most evident in the current rationale of the treatment 
effects of MDMA-assisted psychotherapy. MDMA increases 
cortisol, prolactin, oxytocin, dopamine, norepinephrine, and 
serotonin which in turn increases empathy and self-confidence 
and reduced feelings of anxiety and depression. This allows 
clients to revisit memories and experiences while staying 
emotionally engaged without being overwhelmed by negative 
emotions which may facilitate memory reconsolidation 
(Mithoefer, 2017; Thal and Lommen, 2018).
Based on clinical experiences with clients who have undergone 
SAPT with serotonergic psychedelics, Sandison (1959) has 
suggested that early memories could be re-experienced in vivid 
detail. While these memories are likely a mixture of facts and 
fantasies that contain archetypical experiences, these experiences 
(Spencer, 1964) may allow for acceptance of more important 
emotional connotations (see Sections “Personal Significance, 
Insights, and Meaningfulness” and “Mindfulness and Acceptance”) 
and thus result in personal growth regardless of their factual 
truth. Similarly, positive effects of abreaction itself under the 
influence of certain substances may not be  dependent on the 
factual truth of the traumatic incident, but rather linked to 
the release and re-assessment of trauma-related emotions (see 
also Mithoefer, 2017). Curiously, describing specific episodic 
content of the psychedelic experience is usually more difficult 
than illustrating its cognitive and emotional impact (Bogenschutz 
et  al., 2018). However, the ineffability of the experience does 
not seem to impact its treatment effects or its perceived 
meaningfulness (Malone et  al., 2018).
In contrast, a placebo-controlled crossover study with 
20 healthy participants by Speth et  al. (2016) found that 
the intensity of the LSD experience was positively correlated 
with reduced mental time travel to past events. The authors 
argue that mind-wandering to past events may be  more 
specific but less frequent under LSD. Since ruminating 
about past events is linked to reduced happiness 
(Killingsworth and Gilbert, 2010), psychedelics may display 
similarities to mindfulness-based therapies and thus foster 
mental focus on the presence (Shapiro et  al., 2006; Soler 
et  al., 2016, 2018). Gasser et  al. (2015) found that, besides 
the cognitive experience, the psychodynamic experience 
(i.e., emergence of unconscious material into consciousness 
and/or reliving of past experiences) and the associated 
abreactions and catharsis plus the peak-experiences (i.e., 
ego dissolution, transcendence of time and space, and the 
sense of having meaningful novel insights), mediated positive 
outcomes in LSD-assisted psychotherapy. Intense emotional 
experiences with a state of well-being, pure presence (i.e., 
existing in the here and now), and freedom from past 
concerns, guilt, anxiety, and depression combined with the 
absence of former tensions had the most significant effect 
on clients. Similar experiences of psychodynamic material, 
catharsis, connection, love, and self-compassion have 
been  reported in clinical investigations with psilocybin 
(Bogenschutz et  al., 2018).
Neuroscientific research suggests that reactivation of past 
memories, reconsolidation through incorporations of new 
emotional responses related to these memories, and reintegration 
through altered behavior in everyday situations may result in 
therapeutic change in non-substance assisted therapy (Lane 
et al., 2015). It is possible that this similar mechanism contributes 
to the change in SAPT as well.
Dreamlike Qualities
Some psychoactive substances have been associated with 
experiences with dreamlike qualities (Jacobs, 1978; Fischman, 
1983; Wilkins et  al., 2011; Carhart-Harris and Nutt, 2014; 
Morris and Wallach, 2014; Kraehenmann, 2017; Kraehenmann 
et  al., 2017; Rodger, 2018; Sanz and Tagliazucchi, 2018) and 
it has been suggested (e.g., Kraehenmann, 2017) that the positive 
effects of dreaming on well-being and social functioning may 
also be  applicable for psychedelics. It is further hypothesized 
that altered self-awareness occasioned by some substances may 
result from perspective-shifts (from first-person to third-person 
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perspective) as is often reported in dreams (Thompson, 2014; 
Sanz and Tagliazucchi, 2018). Kraehenmann (2017) proposed 
that fear extinction and formation of novel extinction memories 
through associative learning in contexts that are not associated 
with fear (Nielsen and Levin, 2007; Levin and Nielsen, 2009) 
and memory reconsolidation (Schiller et  al., 2010; Rolls et  al., 
2013) may be related to similar cognitive processes in psychedelics 
and dreams. These concepts overlap with deconditioning, and 
re-assessment of memories.
THE DEVELOPMENT OF MODELS FOR 
SUBSTANCE-ASSISTED 
PSYCHOTHERAPY
In the literature, models of SAPT have been distinguished 
primarily according to the dose of the active substance (Mangini, 
1998). Low dose SAPTs, or psycholytic therapy (Pahnke et  al., 
1971), and high dose SAPTs or psychedelic therapy, sometimes 
referred to as psychedelic peak-therapy (Sherwood et  al., 1968; 
Pahnke et al., 1971; Grof et al., 1973), each attempt to facilitate 
different processes. In psycholytic therapy, low to medium doses 
of psychoactive substances are used to foster the gradual and 
progressive unfolding of various levels of the unconscious 
activating and accelerating the process of psychodynamic or 
psychoanalytic psychotherapy (Leuner, 1967; Grof, 2000; 
Bogenschutz, 2013; Majić et  al., 2015). Active verbal 
psychotherapy is conducted while the client experiences the 
effect of the substance that is used to facilitate revival and 
abreaction of past experiences and emotional releases, loosen 
defense mechanisms, and deepen introspection and insight. 
This is mediated by the therapist’s interpretation of unconscious 
material (Eisner and Cohen, 1958; Sandison, 1959; Leuner, 
1967; Bogenschutz, 2013). Repeated sessions of SAPT (sometimes 
up to 80) are embedded within a psychodynamic or 
psychoanalytic psychotherapy process (with significantly more 
substance-free than SAPT sessions) stretching over several 
months or years (Chandler and Hartman, 1960; Leuner, 1967). 
This extensive time-frame renders the comparison to other 
models and the isolation of the effects of SAPT-sessions extremely 
difficult. Psycholytic therapy was employed as preferred treatment 
model for patients with less severe disorders, such as 
psychosomatic-, mood-, neurotic-, or personality disorders and 
those with an intellectual interest in the therapeutic process 
(Grinspoon and Bakalar, 1979; Gasser, 1995; Grof, 2000). 
Conveniently, the gradual unfolding of various layers of the 
unconscious may allow for unique insights across a variety of 
domains. In doing so, clients might achieve an enhanced 
understanding of different mechanisms and areas of the mind 
through which alterations in behavior or cognition may 
be  achieved (Grof, 2000). Disadvantages include that this can 
require a long duration of treatment, and lower doses may 
mean clients ignore or resist more challenging qualities of the 
experience. Over the course of therapy, the experience of 
transference may inevitably intensify, leading to a deterioration 
of symptoms and decompensation. Finally, the conventional 
psychodynamic framework of the approach may be challenging 
to apply to more extraordinary experiences that transcend 
interpersonal and verbalizable realms (Grof, 2000). While 
psycholytic therapy has influenced current investigations into 
therapeutic applications of psychoactive substances, it has not 
been employed as the main model in recent clinical trials.
Psychedelic therapy employs high doses of psychoactive 
substances that substantially exceed those administered under 
psycholytic frameworks (although there is a certain variability 
to “low” and “high” doses in reported studies and standardized 
“high” and “low” doses are not distinctly defined). It assumes 
that the therapeutic effect is produced by the facilitation of 
the experience of ego dissolution, also referred to as mystical- 
or peak experience (Griffiths et al., 2006), thereby transcending 
the psychodynamic levels (Grof, 2000). As such, substances 
are only used in one to three sessions (guided by the intended 
effect and the model of treatment being used), while preparation- 
and integration sessions without substances may or may not 
be incorporated (Grof, 2000; Johnson et al., 2008; Bogenschutz, 
2013). While psychotherapy is used to maximize the probability 
of these experiences to occur (Sherwood et  al., 1968; Pahnke 
et  al., 1971; Grof, 2000; Bogenschutz, 2013), the approach is 
not based on classic psychological theories (Leuner, 1967; Majić 
et  al., 2015). The therapist supports the client in surrendering 
to and accepting the experience, but is non-directive and does 
not guide the client towards or away from particular experiences 
(Pahnke et  al., 1971; Rhead et  al., 1977; Bogenschutz, 2013). 
While music is provided, and therapists observe the client 
quietly, verbal interventions are usually not applied during the 
peak-substance effects (Bogenschutz, 2013).
Recent research has used the psychedelic approach 
(Bogenschutz et al., 2018; Nielson and Guss, 2018) as treatment 
for conditions such as addiction disorders and depression 
(Johnson et  al., 2014; Bogenschutz et  al., 2015; Carhart-Harris 
et  al., 2016; Griffiths et  al., 2016). The advantage of the model 
is that, due to the high doses used, clients may be  less likely 
be  able to resist the effect of the substances and may be  more 
likely to completely surrender to the experience. This can allow 
for much more substantial effects in a single session compared 
to psycholytic therapy, which in turn makes psychological and 
environmental factors, i.e., set and setting (see Leary, 1961; 
Hartogsohn, 2016) more important for positive therapeutic 
effects. Due to its non-directive nature, there is no imperative 
for confrontation of psychodynamic conflicts. Instead, a greater 
depth, intensity, and spontaneity of the session has been 
described (Grof, 2000). Disadvantages may include the risk of 
greater emotional upheaval due to the more profound effects 
of the substances and greater physiological risks because of 
the higher doses (depending on the substance, of course). The 
non-directive approach may require the therapist to surrender 
to and support the process rather than focus on techniques 
and methodologies. It is mentioned that this requires a high 
level of expertise and trust in the process and that it is currently 
not clear whether improvements and transformations experienced 
in psychedelic therapies represent temporary shifts, or if deep 
structural psychodynamic changes may be  attained. Although 
the general expectations may be  higher in clients receiving 
this approach, it is impossible to guarantee profound experiences 
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in all clients, which may lead to disappointment. The mechanism 
of action of therapeutic change is still not well understood 
and the entire experience can be  difficult to capture, quantify, 
and integrate (Grof, 2000).
There is considerable overlap between certain fundamental 
assumptions of psycholytic and psychedelic models, leading 
some authors to suggest the approaches might be  blended in 
practice to form an hybrid model (Mechaneck et  al., 1968; 
Metzner, 1998). Non-directive approaches may be  used during 
intense parts of the session, while discussion, interpretive work 
and meaning making may start before the effects of the substance 
have ceased completely (Masters and Houston, 1966; Grof, 
2000; Bogenschutz and Forcehimes, 2017; Nielson and Guss, 
2018). In this case, the adaptability of the therapist based on 
the client’s process would be  vital.
In current models of MDMA-assisted psychotherapy for 
PTSD, this mixed approach has been recommended by Mithoefer 
(2017). The substance-assisted sessions are predominantly 
client-led; clients are encouraged to lie back with eyeshades 
on, focus inwards, and be present with their traumatic memories. 
Therapists gently guide clients to consider particular aspects 
of their traumas, and if necessary a short general discussion 
of the content of the session follows once the effects of the 
substance begin to subside (Mithoefer, 2017; Sessa, 2017; Sessa 
et  al., 2019). There are reported exceptions to this approach. 
In a study by Wagner et  al. (2019) clients alternated between 
spending time focused inside and time focused outside without 
headphones and eyeshades spend in conversation with their 
partner or therapists. In theory, all models for SAPT may 
allow for an incorporation of a variety of different schools 
of psychotherapy.
SIMILARITY BETWEEN PRIMARY 
MECHANISMS OF CHANGE IN VARIOUS 
FORMS OF PSYCHOTHERAPY AND 
MECHANISMS OF CHANGE IN SAPT
Some of the mechanisms presented in the SAPT literature 
may also overlap with putative mechanisms of change posited 
in the non-SAPT psychotherapy literature. In this section 
we  will relate the SAPT mechanisms to four key putative 
mechanisms, each highlighted as a central change mechanism 
by one of the major psychotherapy traditions: insight, cognitive 
restructuring, mindfulness, and experiencing.
Even though there has been a temporal shift from Freudian 
techniques to humanistic orientations (Grof, 2000), most of 
the therapies in the first wave of psychedelic research applied 
historically dominant psychoanalytic models (Roseman et  al., 
2018). Additionally, there have been case studies including use 
of exposure therapy (Costello, 1964), arguments for the 
application of learning theory for behavioral re-programming 
(Grieco and Bloom, 1981), and comparisons between approaches 
used in indigenous cultures using Ayahuasca and transpersonal, 
depth psychological, and parapsychological approaches and 
interpretations (Andritzky, 1989).
In recent studies, humanistic therapies such logotherapy 
(Ross et  al., 2016), as well as CBT models (Johnson et  al., 
2014; Wolff et  al., 2020) and third wave CBT approaches like 
ACT (Hayes and Wilson, 1994; Carhart-Harris and Nutt, 2017; 
Watts et  al., 2017; Sloshower et  al., 2020), DBT which has 
been described as “behavioral translation of Zen”; Nuys, 2007) 
and mindfulness-based cognitive therapy (MBCT; Walsh and 
Thiessen, 2018) or motivational enhancement therapy (MET; 
Bogenschutz et  al., 2015; Sessa et  al., 2019) are used or being 
proposed as therapeutic frameworks. These therapies each 
attempt to target similar mechanisms to those identified as 
potential mechanisms in SAPTs.
Insight in Psychodynamic Therapies
Insight has been considered to be  a central mechanism of 
change, emphasized primarily in the psychodynamic tradition. 
Originally, Freud postulated that symptoms developed from 
repressing unacceptable material. From this perspective, a central 
mechanism of change involved making the repressed unconscious 
material conscious, especially regarding the historical 
developmental origins (Freud, 1920). Since the relational turn, 
this focus has shifted slightly, to specifically highlight the 
importance of insight into internalized relational configurations 
or models of self and other that developed from early experiences 
with attachment figures (Greenberg and Mitchell, 1983).
This focus on change through insight into previously repressed 
material, and insight into the effect of early relationships in 
psychodynamic treatments closely links to the SAPT mechanisms 
we  have identified as re-experiencing of memories and personal 
significance, insights, and meaningfulness. Psychodynamic treatments 
would primarily use genetic interpretations into the developmental 
origins of the difficulty, and transference interpretations into the 
replaying of the relational patterns, to both identify and make 
meaning out of this material. However, with SAPTs we  could 
see the initial process of insight being facilitated by the evocative 
function of the substance. The traditional meaning-making process 
of psychodynamic treatment would be highly relevant integrating 
the evoked material during a subsequent integration stage.
Cognitive Restructuring in Cognitive 
Therapies
The central putative mechanism associated with Cognitive 
Therapy is changing beliefs through reasoning, or cognitive 
restructuring (Ellis, 1962; Beck, 1976). This mechanism has 
primarily been targeted by disputation (Ellis, 1962) and Socratic 
dialogues (Beck, 1976), in which people are lead to examine 
their beliefs through open questioning and evaluating evidence. 
This mechanism overlaps with what we  have identified here 
as reconditioning and perspective-shifts and cognitive flexibility. 
While clearly, the initial shifts in SAPT come from substance 
induced evocation, not through reasoning processes, but the 
overlap of the identified mechanisms suggests that they may 
shift a common mechanism. This also implies that standard 
cognitive techniques may be  relevant to consolidate the 
restructuring and perspective shifts during the integration stage 
of SAPTs.
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Mindfulness in Third Wave Behavioral 
Therapies
There are theoretical affinities between TWBTs (Hayes et  al., 
1999; Segal et  al., 2002) and psychedelic therapy, such as 
their common root in contemplative spiritual practices, and 
the development of mindfulness as a putative mechanism 
of action (Soler et  al., 2016, 2018; Smigielski et  al., 2019). 
In TWBT, the psychological state of mindfulness is developed 
primarily through the practice of mindfulness techniques, 
such as imagining thoughts on a leaf in a stream, and 
meditation. While achieved through a different method, the 
resulting state of mindfulness may be  similar to the state 
observed after the ingestion of psychedelics (Soler et  al., 
2016). This synergy suggests that mindfulness, acceptance, 
and meditation practices, like those included in TWBTs could 
be  used to sustain the state of mindfulness during the 
integration stage of SAPTs (Walsh and Thiessen, 2018; 
Sloshower et  al., 2020; Wolff et  al., 2020).
Therapeutic Relationship Conditions and 
Experiencing in Humanistic-Experiential 
Therapies
Humanistic-experiential therapies, such as Client-centered 
(Rogers, 1966), Gestalt (Perls et al., 1951), and Emotion-Focused 
Therapy (Greenberg and Johnson, 1988; Greenberg et al., 1993) 
have emphasized two key change mechanisms – the therapeutic 
relationship conditions and client experiencing – as central to 
the psychotherapeutic change. Rogers (1959) posited that when 
someone perceives that others’ positive regard for them is 
conditional, then they develop “conditions of worth” reflecting 
how they need to be  in order to be  accepted. Symptoms then 
manifest from needing to distort experience to be  congruent 
with these conditions of worth. From this perspective, healing 
and growth can occur when therapeutic relationship conditions, 
including empathy, unconditional positive regard, and congruence 
(Rogers, 1957), mean that a client does not need to defensively 
distort their experience to be accepted. Thus, it is the therapist 
providing the relational conditions, as the soil for a seed, that 
would allow a client to change.
The second change mechanism is client experiencing, which 
is that healing comes from accessing, feeling and symbolizing 
the previously distorted or disavowed emotions. In recent 
versions of experiential theory, this has been described as 
“changing emotion with emotion,” such that accessing previously 
disavowed emotions is what changes the problematic emotions. 
For example, shame could be  changed by accessing assertive 
anger or compassion (Greenberg, 2015). This requires the safety 
provided by therapeutic conditions as a necessary prerequisite, 
but also then suggests that actively directing clients towards 
their emotional experience through internal focusing (Gendlin, 
1996), or through the use of evocative imagery and enactment 
tasks, such as chairwork (Greenberg et  al., 1993; Perls, 1996), 
further facilitates the change process.
These two mechanisms may also overlap with some of the 
identified SAPT mechanisms, as well as the technique suggestions 
for conducting SAPT. Firstly the perception and receptiveness 
to the Rogerian relational conditions could be  facilitated by 
some substances, such as MDMA (Thal and Lommen, 2018). 
The experiencing mechanism also seems closely tied to the 
SAPT mechanism we  have identified as personal significance, 
insights, and meaningfulness, given that emotions inform about 
things that are personally significant and meaningful. The SAPT 
mechanism of reassessment of memories, could also be considered 
a subset of the experiencing construct, given the memories 
that are often referenced as being reassessed therapeutically in 
SAPT tend to be emotionally salient and development significant 
memories. These overlaps have lead for some to argue that 
substances such as MDMA which functions to enhance the 
sense of connection, meaningfulness and processing of emotions, 
make it a natural adjunct for experiential therapies such as 
emotion focused couples therapy (Almond and Allan, 2019). 
There, awe and peak-experiences potentially amplify emotional 
signals such as compassion to everything as well as fear.
Whilst the other therapeutic modalities seemed to 
be  technically suited to the integration stage of SAPTs; the 
humanistic-experiential techniques most closely relate to those 
that have been described for the administration stage. For 
example, the current treatment-model for MDMA-assisted 
psychotherapy for PTSD (Mithoefer, 2017) and some trials for 
depression and anxiety (Carhart-Harris et  al., 2016; Griffiths 
et  al., 2016; Roseman et  al., 2018; Palhano-Fontes et  al., 2019) 
suggest a framework-free and predominantly non-directive and 
client-centered approach seems especially relevant for SAPTs, 
given the substances function to elicit relevant material. Therefore 
a process following stance, as is typical in humanistic-experiential 
therapies, seems the appropriate for this stage of therapy, and 
that content directive therapeutic techniques could interfere 
the substances eliciting function. The non-directive approach 
of MDMA-assisted psychotherapy can empower clients to 
understand and resolve problems in their lives on their own. 
This may be reflected in enhanced measures of personal strength 
and sense of possibility (Gorman et  al., 2020) and qualitative 
reports suggesting that clients prefer non-directive approaches 
(Watts et  al., 2017).
Synergistic Therapeutic Mechanisms
Nielson and Guss (2018) outline similarities between psychedelic 
therapy, mindfulness-based interventions, and psychoanalysis. 
First, they all evoke altered states of consciousness allowing 
inaccessible parts of the self to be  retrieved. As mentioned 
above, increased cognitive flexibility (i.e., increased bottom-up 
prediction errors) induced by psychedelics may result in 
de-patterning and perspective-shifts, increased insights, and 
personal meaningful re-experiencing of memories. Second, the 
therapist gives shape and direction to the course of the therapy, 
but has limited control over the tools for healing which are 
inherited in the client’s mind (Freud, 1912; Walsh and Grob, 
2006; McCown et  al., 2010). Third, the therapist’s personal 
perception, presence, and experience during the therapeutic 
sessions is used to guide the client and the process (Rubin, 
1985; Kabat-Zinn, 2003; Phelps, 2017). In turns, the creation 
of the ideal set and setting is supported by the therapist, to 
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facilitate an altered state of consciousness that supports the 
unfolding of the inner healing capacities of the client 
(Nielson  and  Guss, 2018).
Moving Towards an Incorporation 
of Various Frameworks
In general, psychotherapy usually produces similar outcomes 
across different orientations and it might be  more effective to 
fit and adapt the intervention to the particular client’s needs 
(APA, 2012). Likewise, the extensive review of the literature 
suggests that the effectiveness or reported benefits of SAPT 
might not be due to the theoretical orientation of the therapist 
per se, but rather derived from important similarities and 
overlap between different schools of psychotherapy and dependent 
on intra- and interpersonal variables (Frank and Frank, 1991; 
Asay and Lambert, 1999; Wampold, 2015). Altered states of 
consciousness often allow clients to employ state alteration 
(Jiang et  al., 2017) to change their point of view on an issue 
(as in cognitive restructuring with hypnosis; Spiegel, 2013) or 
experience negative events and let feelings pass without struggling 
against them (as in mindfulness; Paulson et al., 2013). Further, 
memory reactivation, reconsolidation, and reintegration (Lane 
et  al., 2015) during SAPT may aid therapeutic change. This 
can be aided by CBT, interpersonal psychotherapy, psychodynamic 
psychotherapy, emotion-focused-therapy, or hypnosis and 
mindfulness (Lane et  al., 2015; Spiegel, 2016). Providing a 
framework in which the client’s problems can be  understood 
may be  more important than a particular orientation (Ludwig 
and Levine, 1965a).
CONCLUSION
In this narrative review, we have outlined valuable prerequisites 
for thepsists who are considering engaging in SAPT that 
comprise a preset of knowledge and considerations for 
investigations and interventions. In doing so, several approaches 
to SAPT have been outlined to illustrate how literature on 
various schools of psychotherapy can be linked to the literature 
we  reviewed about SAPT. Thereby, similarities across models 
and therapeutic orientations were highlighted. From this review, 
it may be  suggested that various schools of psychotherapy 
could be  incorporated into the development of respective 
therapeutic models. We  hope this provides a basis for the 
development and adaptation of future investigations, therapeutic 
models, training programs for therapists, and those interested 
in the therapeutic potential of SAPT.
There are limitations to the findings outlined above since 
the mechanisms of action and therapeutic models depicted in 
this article have yet to be  validated and further investigation 
employing rigorous research is required. Moreover, comorbidity 
is a common issue with substance use, anxiety, mood disorders, 
and post-traumatic stress (Rytwinski et  al., 2013; Lai et  al., 
2015) – the very conditions for which current clinical 
investigations of SAPT are being conducted. It may be  argued 
that comorbidity between disorders could facilitate the therapeutic 
application of SAPT across disorders (Breeksema et  al., 2020). 
Palhano-Fontes et  al. (2019), for instance, reported that five 
participants with TRD and comorbid borderline personality 
disorder who received Ayahuasca showed significant decreases 
in clinical symptomps of depression 7 days post treatment. 
However, treatment of comorbid disoders introduces unique 
challenges in terms of diagnoses and screening (e.g., Shivani 
et  al., 2002; Wu and Fang, 2014), effective treatments (e.g., 
Roberts et al., 2015), and potential side-effects (e.g., with bipolar- 
and/or psychotic disoders). More research regarding the potential 
harms and benefits of SAPT for the treatment for comorbid 
disorders and potential transdiagnostic approaches (Dalgleish 
et  al., 2020) is needed. Another limitation pertains to TRD: 
many forms of TRD belong to the bipolar spectrum and some 
have argued that treatment-resistant unipolar depression may 
be  considered a prodromal phase of bipolar disorder (Dudek 
et  al., 2010). Non-diagnosed bipolarity was further identified 
as an independent risk factor for treatment resistance in TRD 
(Bennabi et al., 2015). The diagnostic distinction between unipolar 
depression and bipolar depression is of utmost importance 
because antidepressant medication, commonly used for the 
treatment of unipolar depression, may induce mania, hypomania, 
insomnia, and irritability in those with bipolar depression 
(Ghaemi et  al., 2000; Pacchiarotti et  al., 2013). Since some 
people with bipolar diosder may experience psychotic episodes 
after substance use (Starzer et  al., 2018), it is listed as a 
contraindication for most clinical investiations applying SAPT. 
However, the safety and efficacy of psilocybin is currently 
investigated for those with biploar disorder type 2.1 For the 
treatment of TRD with SAPT, the identification of unipolar 
and bipolar depression (especially bipolar depression type 1) 
has to be  closely monitored during the screening process and 
more research is needed to improve screening for and treatment 
of bipolar depression with SAPT.
We have outlined the mechanisms of change in SAPT 
that have been identified in the literature and their similarity 
to mechanisms of change described in traditional psychotherapy. 
Through this analysis it was highlighted that different traditional 
therapeutic approaches and techniques might be  effectively 
combined with and related to certain stages of SAPT and 
different therapeutic outcomes. The purposeful application 
and investigation of different approaches and techniques and 
their relation to therapeutic outcomes should be  assessed in 
the future.
Furthermore, current literature may suggest that like traditional 
psychotherapy, the therapeutic effect of SAPT may not only 
be  mediated by specific substances, therapeutic orientations, 
or models per se; rather the therapeutic effect may depend 
on factors like the therapeutic- and interpersonal relationship, 
empathy, therapeutic presence, and unconditional acceptance 
(Asay and Lambert, 1999; Geller and Greenberg, 2012; Wampold, 
2015). Despite the validation of current standardized models, 
future research should investigate these intersecting variables 
across models, as well. Careful attention to pre-screening, 
contextual factors (i.e., set and setting), substance and dosage, 
as well as preparation (intentions) and integration (meaning) 
1 https://clinicaltrials.gov/ct2/show/NCT04433845
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of the experience are commonalities across different models 
of SAPT (Bogenschutz and Ross, 2016) and thought to be  key 
determinants of the therapeutic outcome (Bogenschutz and 
Forcehimes, 2017). Combining these key determinants with 
common factors that are important for producing positive 
treatment outcomes in psychotherapy such as therapeutic 
relationship, empathy, expectations, and therapist differences 
(Wampold, 2015), may be  important to allow for the broader 
application of SAPT across different models of psychotherapy 
(that share these common factors). Consequently, future studies 
should, as a standard, include valid measures of the therapeutic 
relationship (Horvath and Greenberg, 1989), therapeutic presence 
(Geller et al., 2010), empathy (Dziobek et al., 2008), expectations, 
and personality factors of therapist and client (e.g., Benjamin 
et  al., 2006) in order to assess their potential influence on 
the treatment outcome. Eventually, it is conceivable that certain 
substances (or their combination) will be  more compatible 
with certain therapeutic approaches and/or clinical targets, 
synergistically fostering particular mechanisms. Thus far, no 
controlled studies have been conducted in which different 
models of psychotherapy have been compared using the same 
compound, or in which different substances have been compared 
using the same models of psychotherapy. More research is 
needed to determine which substances and forms of therapy 
may be  effectively combined.
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